Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Networks of intergenic long-range enhancers and snpRNAs drive castration-resistant phenotype of prostate cancer and contribute to pathogenesis of multiple common human disorders.

Glinskii AB, Ma S, Ma J, Grant D, Lim CU, Guest I, Sell S, Buttyan R, Glinsky GV.

Cell Cycle. 2011 Oct 15;10(20):3571-97. doi: 10.4161/cc.10.20.17842.

2.

Junk DNA and the long non-coding RNA twist in cancer genetics.

Ling H, Vincent K, Pichler M, Fodde R, Berindan-Neagoe I, Slack FJ, Calin GA.

Oncogene. 2015 Sep 24;34(39):5003-11. doi: 10.1038/onc.2014.456. Epub 2015 Jan 26. Review.

3.

Activation of endogenous human stem cell-associated retroviruses (SCARs) and therapy-resistant phenotypes of malignant tumors.

Glinsky GV.

Cancer Lett. 2016 Jul 1;376(2):347-59. doi: 10.1016/j.canlet.2016.04.014. Epub 2016 Apr 12. Review.

PMID:
27084523
4.

Prostate cancer: from the pathophysiologic implications of some genetic risk factors to translation in personalized cancer treatments.

Balistreri CR, Candore G, Lio D, Carruba G.

Cancer Gene Ther. 2014 Jan;21(1):2-11. doi: 10.1038/cgt.2013.77. Epub 2014 Jan 10. Review.

PMID:
24407349
5.

Dysregulation of the homeobox transcription factor gene HOXB13: role in prostate cancer.

Decker B, Ostrander EA.

Pharmgenomics Pers Med. 2014 Aug 5;7:193-201. doi: 10.2147/PGPM.S38117. eCollection 2014. Review.

6.

Lingering Questions about Enhancer RNA and Enhancer Transcription-Coupled Genomic Instability.

Rothschild G, Basu U.

Trends Genet. 2017 Feb;33(2):143-154. doi: 10.1016/j.tig.2016.12.002. Epub 2017 Jan 10. Review.

PMID:
28087167
7.

Potency analysis of cellular therapies: the emerging role of molecular assays.

Stroncek DF, Jin P, Wang E, Jett B.

J Transl Med. 2007 May 30;5:24. Review.

Supplemental Content

Support Center